Medical therapies, including established neurohormonal blockers and new developments like angiotensin receptor neprilysin inhibitors, significantly reduce morbidity and mortality in HFrEF.
This review summarizes the established disease-modifying therapies for HFrEF and highlights new developments such as ARNI and treatments for comorbidities.
Heart failure with reduced ejection fraction (HFrEF) is a common cardiovascular condition with a significant individual and societal burden. Although it was previously known as a palliative condition, medical drug therapies that were developed in the last four decades significantly reduced morbidity and mortality of the disease. The cornerstone of HFrEF therapy remains the blockade of the renin-angiotensin-aldosterone and the β-adrenergic systems. This review aims to give an overview and update on established disease-modifying therapies in HFrEF, discuss advances and setbacks in the treatment of selected comorbidities and provide an outlook on upcoming therapies including the new concept of dual angiotensin receptor and neprilysin inhibition.
Naegele et al. (Sun,) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Medical therapy (neurohormonal blockers, MRAs, ARNIs) was evaluated. Medical therapies, including established neurohormonal blockers and new developments like angiotensin receptor neprilysin inhibitors, significantly reduce morbidity and mortality in HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: